Cargando…
Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359438/ https://www.ncbi.nlm.nih.gov/pubmed/33460505 http://dx.doi.org/10.1111/jdv.17124 |
| _version_ | 1783737551438217216 |
|---|---|
| author | Cantrell, W. Lee, P. Mendelsohn, A.M. Rozzo, S.J. Liao, W. |
| author_facet | Cantrell, W. Lee, P. Mendelsohn, A.M. Rozzo, S.J. Liao, W. |
| author_sort | Cantrell, W. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8359438 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83594382021-08-17 Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1 Cantrell, W. Lee, P. Mendelsohn, A.M. Rozzo, S.J. Liao, W. J Eur Acad Dermatol Venereol Letters to the Editor John Wiley and Sons Inc. 2021-02-12 2021-08 /pmc/articles/PMC8359438/ /pubmed/33460505 http://dx.doi.org/10.1111/jdv.17124 Text en © 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letters to the Editor Cantrell, W. Lee, P. Mendelsohn, A.M. Rozzo, S.J. Liao, W. Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1 |
| title | Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1 |
| title_full | Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1 |
| title_fullStr | Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1 |
| title_full_unstemmed | Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1 |
| title_short | Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1 |
| title_sort | efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in resurface 1 |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359438/ https://www.ncbi.nlm.nih.gov/pubmed/33460505 http://dx.doi.org/10.1111/jdv.17124 |
| work_keys_str_mv | AT cantrellw efficacyandsafetyoftildrakizumab100mgforplaquepsoriasisinpatientsrandomizedtotreatmentcontinuationvstreatmentwithdrawalwithretreatmentuponrelapseinresurface1 AT leep efficacyandsafetyoftildrakizumab100mgforplaquepsoriasisinpatientsrandomizedtotreatmentcontinuationvstreatmentwithdrawalwithretreatmentuponrelapseinresurface1 AT mendelsohnam efficacyandsafetyoftildrakizumab100mgforplaquepsoriasisinpatientsrandomizedtotreatmentcontinuationvstreatmentwithdrawalwithretreatmentuponrelapseinresurface1 AT rozzosj efficacyandsafetyoftildrakizumab100mgforplaquepsoriasisinpatientsrandomizedtotreatmentcontinuationvstreatmentwithdrawalwithretreatmentuponrelapseinresurface1 AT liaow efficacyandsafetyoftildrakizumab100mgforplaquepsoriasisinpatientsrandomizedtotreatmentcontinuationvstreatmentwithdrawalwithretreatmentuponrelapseinresurface1 |